-
公开(公告)号:US20160145268A1
公开(公告)日:2016-05-26
申请号:US14899719
申请日:2014-06-20
申请人: LUPIN LIMITED
发明人: Nageswara Rao IRLAPATI , Nilesh Raghunath KHEDKAR , Ravindra Babanrao JAPE , Rahul Shripad NANDURDIKAR , Zubair Abdul Wajid SHAIKH , Neelima SINHA , Venkata P. PALLE , Rajender Kumar KAMBOJ
IPC分类号: C07D498/04 , C07D413/04 , C07D265/36 , C07D413/14 , C07D413/12 , C07D263/58 , C07D417/04
CPC分类号: C07D498/04 , A61K31/5377 , C07D263/58 , C07D265/36 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04
摘要: The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CR3 or N; Y is CR3 or N; L is selected from —NR2C(O)—, —C(O)NR2— and —NR2CRaRb—; Ra and Rb are independently hydrogen, halogen or substituted or unsubstituted alkyl; ring E is selected from the Formula (i) to (vii).
摘要翻译: 本发明涉及式(I)化合物及其药学上可接受的盐,其中取代基如本文所述,及其在药物中的用途,用于治疗与调节钙释放激活的钙(CRAC)通道相关的疾病,病症 。 本发明还涉及含有这些化合物在治疗与钙释放激活的钙(CRAC)通道调节剂相关的疾病障碍中的药物组合物。 其中环D为式(a)或式(b):A和B可以相同或不同,独立地为CR 3或N; Y是CR3或N; L选自-NR 2 C(O) - , - C(O)NR 2 - 和-NR 2 CR a R b - ; R a和R b独立地是氢,卤素或取代或未取代的烷基; 环E选自式(i)至(vii)。
-
公开(公告)号:US20160304507A1
公开(公告)日:2016-10-20
申请号:US15194795
申请日:2016-06-28
申请人: LUPIN LIMITED
发明人: Nageswara Rao IRLAPATI , Gokul Keruji DESHMUKH , Nilesh Raghunath KHEDKAR , Kiran Chandrashekhar KULKARNI , Zubair Abdul Wajid SHAIKH , Neelima SINHA , Venkata P. PALLE , Rajender Kumar KAMBOJ
IPC分类号: C07D413/14 , C07D401/14
CPC分类号: C07D413/14 , C07D401/14
摘要: The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.
-